comparemela.com

Latest Breaking News On - Noria therapeutics inc - Page 2 : comparemela.com

Radiopharmaceuticals Market to cross US$ 6 2 Bn by 2022, Says Future Market Insights

Radiopharmaceuticals Market to cross US$ 6 2 Bn by 2022, Says Future Market Insights

Radiopharmaceuticals Market to cross US$ 6 2 Bn by 2022, Says Future Market Insights
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.

Bayer acquires Noria, PSMA Therapeutics

Bayer acquires Noria, PSMA Therapeutics Deal expands prostate cancer pipeline June 4, 2021 9:31 am Bayer said June 3 it agreed to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc., through which the Whippany-based company will broaden its existing oncology portfolio of targeted alpha therapies. The deal, for which financial details were not disclosed, will see Bayer pick up exclusive rights to two investigational therapies for prostate cancer that will complement the already approved therapy Xofigo, according to a release from the company. Targeted alpha therapies, or TATs, treat difficult tumors by delivering alpha radiation inside the body using either a bone-seeking property or through the combination of alpha radionuclides with specific molecules.

Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria

Published: Mar 30, 2021     NORTH BILLERICA, Mass. (BUSINESS WIRE) Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced today it has acquired the exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, an innovative PET oncology imaging agent from Noria Therapeutics, Inc. NTI-1309 targets fibroblast activation protein (FAP), a target with potential broad imaging applicability and targeting implications in oncology. FAP is overexpressed in the tumor microenvironment, specifically in tumor-associated fibroblasts, which are believed to modulate tumor progression and immune response. Given its expression in tumors coupled with low expression in normal tissue, FAP has the potential to become an important biomarker for precision medicine in cancer.

Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria

Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.